# Monte Rosa Therapeutics share price today (Monte Rosa Therapeutics, Inc., GLUE)

> Monte Rosa Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. GLUE · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/glue

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $10.82 (−12.1% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: ₹0.0 B (one-off item, see below)
- Operating margin: −547.8% (−480.7 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Monte Rosa Therapeutics share price today? Monte Rosa Therapeutics, Inc.'s share price was $10.82 at the close on 4 November 2026. It has been moving sideways for 15 weeks. That is 37.0% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 15 weeks running. In the last 52 weeks it traded between $10 and $25, and at that close it sat 7% of the way up from that low. Over the last 5.4 years the share price moved −43% while the S&P 500 moved +72%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 24 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Monte Rosa Therapeutics pay? Monte Rosa Therapeutics, Inc. pays no dividend. In the last 10 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Monte Rosa Therapeutics on? Monte Rosa Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Monte Rosa Therapeutics profitable? Monte Rosa Therapeutics, Inc. posted a net loss of ₹0.04 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.04 B. That loss is 483.9% of the quarter's revenue. The same quarter a year earlier lost ₹0.01 B. 8 of the last 10 reported quarters were loss-making. Jun 2026 profit was ₹0.0 B. For the full year, FY25 profit was ₹0.0 B. Read this profit with care: at ₹0.0 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −547.8% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Monte Rosa Therapeutics make, and is it growing? Monte Rosa Therapeutics, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, −61.3% on the same quarter a year earlier. Over 1 years it has grown 63.5% a year on average. The last full year, FY25, came in at ₹0.1 B. The last four reported quarters add to ₹0.0 B. Recent pace: the last four quarters grew −53.3% on average, against 63.5% a year over the longer run, so this year is growing slower than its own long-run rate. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Monte Rosa Therapeutics keep? Monte Rosa Therapeutics, Inc.'s operating margin was −547.8% in the Jun 2026 quarter, 480.7 percentage points lower than the same quarter a year ago. Across 2 years it has been between −107.3% and −43.8%. Why the margin moved: operating margin changed −480.7 percentage points on the year while gross margin changed −387.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Monte Rosa Therapeutics' profit turning into cash? Monte Rosa Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.0 B of cash, against ₹0.0 B of profit. After ₹0.0 B of spending on assets, free cash was ₹0.0 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Monte Rosa Therapeutics' cash go? Monte Rosa Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 2 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 2 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Monte Rosa Therapeutics' P/E ratio, and how does it compare with its own history? Monte Rosa Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Monte Rosa Therapeutics business getting better or worse? Monte Rosa Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 0 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Monte Rosa Therapeutics earn on its capital? Monte Rosa Therapeutics, Inc. earned a ROE of −17% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −561%, a number that says nothing useful about the business. It comes from a −31.2% net margin and 0.28× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −31.2% net margin × 0.28× asset turnover × 1.93× leverage (assets divided by equity) ≈ −16.9% on equity. The margin does its share; borrowing is a big part of it. ## Does Monte Rosa Therapeutics have too much debt? Monte Rosa Therapeutics, Inc. has total debt of ₹0.0 B against shareholder equity of ₹0.5 B as of Jun 2026, so its debt is 0.08× its equity, which is very little. Year by year, that ratio went from 0.17 in FY22 to 0.17 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Monte Rosa Therapeutics shareholding pattern? 37.9% of Monte Rosa Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 14.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Monte Rosa Therapeutics from balance-sheet trouble? For Monte Rosa Therapeutics, Inc., the Z-score is 2.09. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.09 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Monte Rosa Therapeutics rank in its industry? There is no score against its industry: Monte Rosa Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Monte Rosa Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Monte Rosa Therapeutics in size? Monte Rosa Therapeutics is the 113th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Syndax Pharmaceuticals, Inc., Inventiva S.A. and Odyssey Therapeutics, Inc. Just below it: MeiraGTx Holdings plc, Prime Medicine, Inc. and Theravance Biopharma, Inc. ### Biotechnology companies close in size

1. [Syndax Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/sndx) $941 million
2. [Inventiva S.A.](https://www.sectoralpha.in/us/stocks/iva) $940 million
3. [Odyssey Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/odtx) $934 million
4. Monte Rosa Therapeutics, Inc. $923 million
5. [MeiraGTx Holdings plc](https://www.sectoralpha.in/us/stocks/mgtx) $905 million
6. [Prime Medicine, Inc.](https://www.sectoralpha.in/us/stocks/prme) $884 million
7. [Theravance Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/tbph) $884 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [NB Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/nbbk) $928 million · Banks - Regional
2. [Compass Diversified](https://www.sectoralpha.in/us/stocks/codi) $926 million · Conglomerates
3. Monte Rosa Therapeutics, Inc. $923 million
4. [Beta Bionics, Inc.](https://www.sectoralpha.in/us/stocks/bbnx) $922 million · Medical Devices
5. [Bumble Inc.](https://www.sectoralpha.in/us/stocks/bmbl) $919 million · Internet Content & Information

## What else do people ask about Monte Rosa Therapeutics? ### What were Monte Rosa Therapeutics's latest quarterly results? Monte Rosa Therapeutics, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.0 B for the Jun 2026 quarter. The operating margin was −547.8%, 480.7 percentage points lower than a year earlier (as of 4 November 2026). ### What is Monte Rosa Therapeutics's market cap? Monte Rosa Therapeutics, Inc.'s market capitalisation is $923 M at a stock price of $10.82. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Monte Rosa Therapeutics performing? Monte Rosa Therapeutics, Inc.'s share price has been moving sideways for 15 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 15 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Monte Rosa Therapeutics's stock price go up? This page does not forecast Monte Rosa Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $10.82, and it has been moving sideways for 15 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Monte Rosa Therapeutics in its business cycle? Monte Rosa Therapeutics, Inc.'s FY25 operating margin was −43.8%, against a 2-year range of −107.3% to −43.8%: the middle of its own range, neither a peak nor a low. The latest quarter was −547.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Monte Rosa Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Monte Rosa Therapeutics a stock worth studying right now? What the numbers show: Monte Rosa Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.